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Introduction
It was shown recently that some primary antibody deficiencies are caused by hyperactivation of the PI3K signaling pathway, as gainof-function mutations in PIK3CD encoding for the p110δ subunit result in activated PI3Kδ syndrome (APDS) (1, 2) . Class IA PI3K molecules are composed of a p110 catalytic subunit (p110α, p110β, or p110δ) and a regulatory subunit (p85α, p55α, p50α, p85β, or p55γ) that regulates p110's stability, cellular localization, and function. Each of the catalytic subunits can bind to any of the regulatory subunits. Expression of the p110δ catalytic subunit is restricted mainly to leukocytes, whereas p110α and p110β are ubiquitously expressed (3) . The function of class IA PI3Ks is to convert phosphatidylinositol 4,5-bisphosphate into phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), a phospholipid secondary messenger that interacts with intracellular enzymes containing pleckstrin homology domains. The most important of these enzymes is the serine/ threonine kinase AKT, whose important role in cell proliferation, growth, survival, and metabolism in many cell types has been conserved throughout evolution (3) . PI3K signaling notably has an important role in several distinct stages of B and T cell development, differentiation, and function, and their activation occurs downstream of the antigen receptor (either the B cell receptor [BCR] or TCR) and costimulatory molecules (4) . The expression of an active form of p110α was enough to maintain B cell survival in the periphery in the absence of a BCR, highlighting the importance of PI3K for B lymphocytes (5) . Furthermore, PI3K signaling has an important role in the antibody maturation process, because it is involved in the regulation of Ig class switch recombination and plasma cell differentiation (6) . It was reported recently that a patient presenting with agammaglobulinemia and the absence of B lineages carried a premature stop codon in PIK3R1, resulting in the absence of p85α (7) . PIK3R1 encodes p85α and 2 additional isoforms (p55α and p50α), the production of which is regulated by 2 distinct promoters and alternative first exons. The last nine 3′ exons of PIK3R1 are expressed in all isoforms (7) .
Results and Discussion
Patients. All 4 patients had been suffering from recurrent respiratory bacterial tract infections from soon after birth, although none of them was hospitalized to treat infections (Table 1 and Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI75746DS1). They had no signs of allergy, autoimmunity, splenomegaly, or lymphadenopathy (with the exception of patient 1 [P1], whose tonsils had been removed in 2 separate operations). Although viral infections and opportunistic bacterial or fungal infections were not reported, P2, but not P1 and P4, presented with CMV and EBV viremia, as detected by PCR (CMV, 9,300 copies per ml; EBV, 1,500 copies per ml; reference values, <446 and <182, respectively). Lymphocyte counts were in the normal range, but the frequency of CD31 + CD45RA + naive CD4 and CCR7 + CD45RA + naive CD8 peripheral blood T cells was low in all patients (Table 1 ). An elevated proportion of CD8 T cells
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Identification of a heterozygous gain-of-function mutation in PIK3R1. By applying whole-exome sequencing (Supplemental Methods) and then targeted Sanger sequencing, we identified 2 different heterozygous splice site mutations affecting the same splice site in PIK3R1 (Figure 1, A Values outside the normal range are given in bold. A IgG1 = 6.6 g/l (>4 g/l); IgG2 = 6.7 g/l (>0.6 g/l); IgG3 = 0.78 g/l (>0.17 g/l); IgG4 = 0.02 g/l (0-2. stimulation with an anti-CD3 antibody, the level of phosphorylation of AKT at Ser473 in patients' cells was comparable to that in control cells when analyzed by immunoblotting but consistently higher in patients' cells than in control cells when analyzed by flow cytometry (Figure 2 , A and B, and Supplemental Figure 4 , A-C). Phosphorylation of AKT was also higher in patients' cells than in control cells following a 30-minute stimulation with anti-CD3 and anti-CD28 antibodies when analyzed by flow cytometry (Supplemental Figure 5A ). Phosphorylation of AKT was no longer detected by flow cytometry in patients' or control cells when the PI3Kδ inhibitor IC87114 was present in a high concentration during the activation ( Figure 2B) or added for the last 20 minutes of stimulation (Supplemental Figure 5A ). Lower concentrations of the inhibitor strongly but not completely abrogated phosphorylation of AKT at Ser473, arguing for p110δ-independent AKT phosphorylation (Supplemental Figure 5B ). Figure 3A) . A lower amount of mutant protein p85α Δ434_475 in comparison with that of WT p85α was also observed in transfection experiments in 293T cells, indicating that the mutant protein is less stable (Supplemental Figure 3B ). The description of heterozygous mutations, including a series of overlapping in-frame deletions, in exon 10 of the PIK3R1 gene in cancer cells supports the hypothesis whereby this novel splice site mutation is disease causing (9, 10). These mutations do not affect p85α's ability to stabilize p110 but abrogate inhibitory activity and thus promote AKT activation (10) . To test the hypothesis in which p85α Δ434_475 behaves similarly to the mutant p85α proteins found in cancer cells, we examined the abundance of p110δ protein and phosphorylation of AKT at Ser473 in the patients' T cell blasts. The expression of p110δ was found to be normal. Phosphorylation of AKT at Ser473 and Thr308 was detected in nonstimulated patients' cells but not in nonstimulated control cells. Following period of time ( Figure 2D ). Elevated levels of AICD were observed at a lower intensity when the inhibitor IC87114 was added 15 minutes before stimulation ( Figure 2D) , indicating that the cell death was, to a large part, a consequence of stronger PI3Kδ signaling.
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Impaired T and B lymphocyte proliferation in vitro.
To study the effect of the PIK3R1 splice site mutation on B and T lymphocyte function, we examined the in vitro proliferation activity of the patients' peripheral blood lymphocytes after exposure to various stimuli. As assessed by the loss of CFSE fluorescence intensity after cell stimulation with CD40L and IL-4, the proliferative activity of the patients' B cells was similar to that of healthy controls. In contrast, low proliferative activity was observed when the patients' B cells were activated with anti-IgM plus CpG oligonucleotides, indicating that p85α Δ434_475 interferes with signaling through the BCR and/or the TLR9 ( Figure 3A) . Impaired proliferation activity (relative to controls) was also observed when the patients' CD8 T cells were stimulated with anti-CD3-and anti-CD28-coated beads ( Figure 3B ). It remains to be established whether the decreased proliferative activity of CD8 T cells results from more intense PI3K signaling. Indeed composition of peripheral blood cells was biased Hyperactivated PI3K/AKT signaling in T cell blasts has been reported to result in increased mTORC1 signaling (2) . We indeed found elevated phosphorylation of the ribosomal protein S6 at Ser240 and Ser244 in nonstimulated patients' cells compared with that in nonstimulated control cells, indicating increased mTORC1 signaling (Supplemental Figure 5, C and D) .
To confirm that the shortened protein p85α Δ434_475 was responsible for the hyperactivation of AKT, we ectopically expressed the mutant and WT form of p85α in NIH3T3 cells. We found elevated levels of phosphorylated AKT in the cells expressing p85α Δ434_475 in comparison with controls ( Figure 2C) . These results strongly suggest that the PIK3R1 splice site mutation is a disease-causing mutation that increases PI3K signaling.
Increased cell death following T lymphocyte activation. Given that mutations in p110δ result in increased PI3K signaling and greater susceptibility of T cell blasts to activation-induced cell death (AICD), we measured the latter phenomenon in T cell blasts from patients carrying the PIK3R1 splice site mutations. After stimulation with anti-CD3, the patients' T cell blasts displayed higher levels of AICD than control blasts cultured for the same The results are expressed as the percentage of apoptotic/dead blasts after OKT3 activation minus the percentage of apoptotic/ dead blasts in the absence of stimulation. AICD was analyzed with or without 3 μM IC87114 inhibitor with T cell blasts cultured for 6 days. Similar results were obtained at later time points and for P2 and P3 (data not shown).
Mutations in PIK3R1, which either impair p85α function or completely abrogate p85α expression, cause primary antibody deficiencies (hypogammaglobulinemia or agammaglobulinemia, respectively). Agammaglobulinemia is the result of severely impaired B cell development, and such a B cell intrinsic effect in patients carrying homozygous loss-of-function mutation results in nearly complete PI3K deficiency (7) . In contrast, the variable hypogammaglobulinemia observed in patients carrying heterozygous PIK3R1 splice site mutations is the result of activated p110 and can be explained by (a) an intrinsic B cell defect (impaired B cell development/differentiation and responses to BCR and TLR stimuli); (b) an extrinsic B cell defect, e.g., defective T cell function (increased AICD); or (c) a combination of B cell intrinsic and extrinsic defects.
Given that B cell lymphoma has been reported in APDS, patients carrying a heterozygous PIK3R1 splice site mutation are also at risk of carcinogenesis (1, 2) . The spectrum of disorders might be broader, since p85α can also interact with p110α and p110β; this might lead to hyperactivation of PI3K signaling in other cell types. Our present work describes a new genetic defect toward effector T cells, which are known to be less able to proliferate after TCR stimulation in vitro (relative to naive T cells) (11) .
The phenotype of the patients described herein appears to be a phenocopy of that seen in APDS, including phenotypic heterogeneity that may be related to the patient's history of infections, environmental factors, and/or the presence of modifier genes. Considering the broad expression of PIK3R1-derived regulatory components and their implication in many signal transduction pathways, a nonlymphocyte component might contribute to the phenotype.
The PI3K signaling product PIP 3 is dephosphorylated by the phosphatase and tensin homolog (PTEN) (12) . The p85α regulatory protein also binds to PTEN and enhances the latter's lipid phosphatase activity, making it a dual regulatory protein for both the PI3K p110 catalytic subunit and PTEN. Hence, p85α has a critical regulatory function in maintaining the balance of PI3K/PTEN signaling (13) . The PTEN protein abundance was normal in P1's T cell blasts (Supplemental Figure 6 ). It remains to be seen to what extent the p85α Δ434_475 mutant protein impairs PTEN activity and thereby strengthens PI3K signaling. responsible for an immunodeficiency that is caused by activating mutations in PIK3R1 and increased PI3K signaling. We suggest naming this new immunodeficiency "activated PI3Kδ syndrome 2" (APDS2), since uncontrolled activity of p110δ is (at least to a large part) responsible for the disease. Our results highlight the role of PI3K signaling in the homeostasis of immune responses. Further screening for defects that lead to hyperactivation of PI3K signaling should therefore be performed in other patients with similar primary immunodeficiencies and no known genetic defect.
Methods
Further details are provided as Supplemental Methods. Statistics. Analyses were performed with PRISM software (version 4 for Macintosh, GraphPad Inc.). Statistical hypotheses were tested using 2-tailed t test. A P value of less than 0.05 was considered significant.
Study approval. Peripheral blood samples were obtained from the patients, their relatives, and healthy donors after the provision of informed, written consent. Genetic studies and data collection procedures were approved by the Comité de Protection des Personnes Ile de
